by Raymond Tel | Oct 24, 2018 | News
Hibernation research leads to new medicines preventing Alzheimer, Diabetes Type 2 and acute kidney injury ‘Kidney tubule cells from hibernators have an increased resistance to oxidative stress compared to non-hibernators. Based on our research into hibernation, we...
by Raymond Tel | Oct 15, 2018 | News
Cooperation Sulfateq and UMCG recognizes with an Industrial Doctorates grant Last August 2018, the Netherlands Organization for Scientific Research (NWO) awarded an Industrial Doctorate grant to a collaborative project between Sulfateq B.V. and the group of Prof. dr....
by Raymond Tel | Oct 15, 2018 | Uncategorized
Samenwerking Sulfateq en UMCG erkent met een Industrial Doctorates subsidie Afgelopen augustus 2018 is door de Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) een Industrial Doctorate beurs toegekend aan een samenwerkingsproject tussen Sulfateq B.V. en...
by Raymond Tel | Oct 20, 2017 | News
The international kidney week is right around the corner. From 31 October until 5 November 2017 more than 13.000 kidney professionals from across the globe will come to New Orleans to exchange knowledge about the fight against kidney disease. Acute kidney injury (AKI)...
by Raymond Tel | Sep 15, 2017 | News
In the range of compounds for protecting organs from Sulfateq a new paper is published. We are proud to announce that Dr. L.E. (Leo) Deelman (UMCG) has published his paper on the protective effects of our SUL-121 compound in diabetes. SUL-121 preserves endothelial...
by Raymond Tel | Sep 11, 2017 | News
Tonight (11 September 2017) please tune in to BBC2. At 22:00 (Dutch time), Professor Rob Henning of the UMCG discusses the need for human hibernation. In this episode of “The search for a new world” Christophe meets anaesthesiologist Dr. Rob Henning, who...
by Raymond Tel | Mar 27, 2017 | News
Sulfateq B.V. is dedicated to developing new drugs for several diseases: Acute Kidney Injury (AKI), Chronic Obstructive Pulmonary Disease (COPD), Type II Diabetes (T2D) and obesity. We can now proudly announce that the SUL-compounds are being tested in sepsis, which...
by Raymond Tel | Jan 17, 2017 | Uncategorized
Lately there is a lot of happening at Sulfateq which is very positive for the development of ROKEPIE. Besides our new website there are also multiple publications and papers which have been published or will be published in the near future. What’s even greater is that...
by Raymond Tel | Nov 1, 2016 | Events, News
From 7 till 9 November 2016 we will be attending BIO-Europe 2016 in Cologne (Germany). BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. Our CEO Kees van der Graaf will be present on these days to talk about business...
by Raymond Tel | Jun 8, 2015 | COPD, Events, Hibernation, News, Poster release, Treatment
We are proud to announce that one of our SUL-compounds, SUL-121, is proven to have both an anti-inflammatory and bronchodilating effect in vitro and in vivo. In the study, performed by the University of Groningen, the researchers explored the anti-inflammatory and...
